Currently, due to the high costs associated with immunological treatments, patient selection for such therapies is guided by therapy response predictors, of which PD-L1 expression levels in tumor cells and inflammatory infiltrate, with a combined expression threshold of >10% typically required for initiating Nivolumab [24,25,26]. Here, CD274 is linked to neoplasm.